Amylyx Pharma Q2 net loss wider than expected as R&D costs increase

Amylyx Pharmaceuticals

07/08/2025 12:12

Overview

Amylyx Q2 net loss of $41.4 mln misses analyst expectations, per LSEG data

EPS for Q2 misses estimates as R&D costs rise

Outlook

Amylyx expects its cash runway to be through the end of 2026

Result Drivers

R&D EXPENSES - Increase primarily due to clinical development of avexitide in PBH and AMX0035 in PSP

SG&A EXPENSES - Decrease attributed to reduced payroll and personnel-related costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$0.46
-$0.45 (8 Analysts)
Q2 Net Income
Miss
-$41.44 mln
-$39.60 mln (7 Analysts)
Q2 Operating Income
Miss
-$42.86 mln
-$40.90 mln (8 Analysts)
Q2 Pretax Profit
Miss
-$41.44 mln
-$40.60 mln (5 Analysts)
Q2 Operating Expenses
$42.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00, about 18.1% above its August 6 closing price of $8.19

Press Release: ID:nBwmMFCPa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)